Drug intelligence / Profile preview

TV005 (National Institute of Allergy and Infectious Diseases)

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TV005 is a tetravalent, live-attenuated dengue vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID). It is designed to provide balanced immunity against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) in a single dose. The vaccine is composed of four specific monovalent components: rDENV1Δ30, rDENV2/4Δ30 (a chimeric virus), rDENV3Δ30, and rDENV4Δ30. These components are attenuated by a 30-nucleotide deletion in the 3' untranslated region of the viral genome. TV005 has been evaluated in various clinical trials for safety and immunogenicity across different age groups and flavivirus-exposure backgrounds, showing high rates of seroconversion to all four serotypes.

Other names: NIAID tetravalent dengue vaccineTetraVax-DV TV005

Targets

Dengue virus serotype 1 structural proteins (DENV-1 structural proteins)DENV-4 (Dengue virus serotype 4)DENV-2 (Dengue virus serotype 2)prM (Dengue virus pre-membrane protein)Dengue virus serotype 3 structural proteins (C, prM, E)

Beyond the preview

Go deeper on TV005 (National Institute of Allergy and Infectious Diseases).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV005 (National Institute of Allergy and Infectious Diseases).

Explore the full profile